You are here: Industry Insights > Janssen Biotech

News List

Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists firstwordpharma
July 29, 2021
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen Biotech, Inc.manufacture and commercialization.
Genmab and Janssen Biotech to develop CD38 antibody pharmaceutical-technology
June 14, 2019
Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).
Janssen hands back rights to imetelstat pharmatimes
September 29, 2018
Janssen Biotech has decided to terminate a collaboration and license agreement with Geron Corp for experimental cancer drug imetelstat.
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castrat biospace
December 26, 2017
Apalutamide is the First Agent Submitted for Approval to Treat Earlier Stage Castration-Resistant Prostate Cancer at High Risk for Metastasis
Janssen Biotech submits NDA to FDA for apalutamide to treat non-metastatic CRPC pharmaceufical-technology
October 13, 2017
Apalutamide is a new investigational, oral androgen receptor (AR) inhibitor that inhibits the action of testosterone in prostate cancer cells and works by preventing androgen from binding to the androgen receptor.
Johnson & Johnson objects to a Janssen-developed drug's use in executions fiercepharma
August 23, 2017
As drugmakers have put contract restrictions on use of their drugs for executions, the half-dozen states that use lethal injection are finding it more difficult to secure supplies.